Newsfile Corp
09 Oct 2026, 15:47 UTC · 1h ago
ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY
Impact · against what's priced in
The news is neutral for The Cooper Companies as the market has already accounted for existing securities law investigations. For Unicycive Therapeutics, the legal proceedings regarding manufacturing failures and potential FDA delays remain a significant negative catalyst.
- COO+0.00
Already priced in
- The price assumes
the ongoing securities law investigation by Hagens Berman





